Poging GOUD - Vrij

Expanding Toolbox Spurring Opportunities

BioSpectrum Asia

|

September 2022

Synthetic biology encompasses myriad technologies combining life sciences, engineering, and chemistry to improve, optimise, or enable the de novo design of artificial cells, organisms and cellular pathways.

Expanding Toolbox Spurring Opportunities

It can be integrated into a multitude of industry segments, support process improvement, and drive the development of new products and processes. Rapid strides in high-throughput, high-fidelity, low-cost DNA and oligo synthesis, DNA printing, genome editing tools, and engineered gene circuits, coupled with advances in digitisation, automation and artificial intelligence (AI), are propelling the SynBio applications.

They have the potential to disrupt the industrial ecosystem in healthcare (drug discovery, diagnostics), energy & environment (bioremediation, clean energy), industrial biomanufacturing (chemicals, flavours, fragrances, biomaterials), and agritech and foodtech (livestock feed, cultured proteins) to name a few. The synthetic biology toolbox has transformed the way the healthcare and life sciences industry functions and has become a ubiquitous tool for basic life sciences research, drug discovery, diagnostics, programmable therapeutics, etc. Within healthcare, next-generation biomanufacturing and advanced therapies can be impacted greatly with seamless integration.

Synthetic biology tools have been around for decades, but it is only in the past few years that they have been actively deployed, bolstering an era of sustainability and enabling the creation of a bioinspired economy. While the US and UK were the initial hubs of R&D and investments for synthetic biology and have well-developed SynBio networks, it has gained momentum in Asia, which expects to witness a surge of R&D activities, partnerships, and product development in the near term (2023-2025).

Growing Ecosystem

MEER VERHALEN VAN BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries

Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Biotium launches GlycoLiner Cell Surface Glycoprotein Labeling Kits

US-based Biotium, a leading innovator in fluorescent dyes and life science reagents, has announced the launch of GlycoLiner Cell Surface Glycoprotein Labeling Kits for rapid, selective, and covalent labeling of cell surface glycoproteins.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO

Australia-based Vaxxas has announced the appointment of global biopharmaceutical executive David Peacock as Chief Executive Officer (CEO) to lead the commercialisation of the company's proprietary high-density microarray patch (HD-MAP) vaccination technology.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Thermo Fisher partners with NVIDIA leveraging AI to advance scientific instrumentation

US-based Thermo Fisher Scientific Inc. has announced a strategic collaboration with NVIDIA to power artificial intelligence (AI)based solutions and laboratory automation at scale.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Bruker consolidates ownership of TOFWERK in expansion of mass spectrometry portfolio

Bruker Corporation has announced the acquisition of an additional 60 per cent ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker's ownership to 100 per cent.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Bioengineered tissue by Japan emerges as revolutionary treatment for secondary lymphedema

A research team led by Associate Professor Kosuke Kusamori from the Faculty of Pharmaceutical Sciences at Tokyo University of Science (TUS), Japan, is pioneering an innovative technique for lymphatic tissue engineering that could revolutionize the treatment of secondary lymphedema.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Chitose and Fujifilm Biosciences to drive global innovation and biopharma manufacturing

Japan-based Chitose Laboratory Corp. & Fujifilm Biosciences Inc. have announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Vibrant Therapeutics on-boards Dr Han Lee as Co-CEO

Vibrant Therapeutics, a clinical-stage biotechnology company based in China and US, has announced the appointment of Dr Han Lee as co-chief executive officer (CEO).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

IIT-D and AIIMS develop swallowable microdevice for microbiome study

Researchers at the Indian Institute of Technology (IIT) Delhi, and All India Institute of Medical Sciences (AIIMS) have developed an ingestible device that can sample bacteria directly from the small intestine, opening a new window into the human gut microbiome.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Ambitious research to develop multivalent vaccines against multiple deadly filoviruses

Scientists at the University of Oxford, in collaboration with partners, will spearhead the development of new vaccines that aim to provide comprehensive protection against multiple lethal filoviruses, including Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus.

time to read

1 min

BioSpectrum Asia Feb 2026

Translate

Share

-
+

Change font size